251326-99-5

Basic information

• Product Name: (1R-4S)-4-[[(1,1-dimethylethoxy)carbonyl]amino]- 2-Cyclopentene-1-carboxylic acid methyl ester
• Synonyms: (1R-4S)-4-[[(1,1-dimethylethoxy)carbonyl]amino]- 2-Cyclopentene-1-carboxylic acid methyl ester;(1R,4S)-Methyl 4-(tert-butoxycarbonylaMino)cyclopent-2-enecarboxylate;Cis-(1R,4S)-4-Boc-aMino-2-Cyclopentene-1-carboxylic acid Methyl ester;Methyl (1R,4S)-4-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-2-cyclopentene-1-carboxylate
• CAS NO: 251326-99-5
• Molecular Formula: C12H19NO4
• Molecular Weight: 241.28356
• EINECS: -0
• Mol File: 251326-99-5.mol

Chemical Properties

• Boiling Point: 331.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• PKA: 11.75±0.40(Predicted)
• CAS DataBase Reference: (1R-4S)-4-[[(1,1-dimethylethoxy)carbonyl]amino]- 2-Cyclopentene-1-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1R-4S)-4-[[(1,1-dimethylethoxy)carbonyl]amino]- 2-Cyclopentene-1-carboxylic acid methyl ester(251326-99-5)
• EPA Substance Registry System: (1R-4S)-4-[[(1,1-dimethylethoxy)carbonyl]amino]- 2-Cyclopentene-1-carboxylic acid methyl ester(251326-99-5)

Safety Data

• Hazardous Substances Data: 251326-99-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1R-4S)-4-[[(1,1-dimethylethoxy)carbonyl]amino]2-Cyclopentene-1-carboxylic acid methyl ester is used as a key intermediate in the synthesis of a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist. This dual antagonist has potential applications in the treatment of various inflammatory and autoimmune diseases, as well as in the development of novel therapeutic strategies for conditions such as HIV and cancer.
The compound's unique structure and functional groups allow it to interact with the CCR2 and CCR5 receptors, blocking their activation and thus modulating the immune response. This dual antagonistic activity makes it a valuable tool in the development of new drugs targeting these receptors, which play a crucial role in the pathogenesis of several diseases.

Upstream product

• 419563-23-8 (1R,4S)-4-aminocyclopent-2-ene-1-carboxylic acid methyl ester tartrate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 49805-30-3 racemic 2-azabicyclo[2.2.1]hept-5-en-3-one 
• 130931-85-0 (+)-(1R,4S)-4-aminocyclopent-2-ene-1-carboxylic acid hydrochloride 
• 200002-41-1 (-)-[(1R,4S)-tert-butyl 3-oxo-2-azabicyclo(2.2.1)hept-5-ene-2-carboxylate] 
• 352226-74-5 4-amino-cyclopent-2-enecarboxylic acid methyl ester 
• 151907-80-1 (1R,4S)-4-[(tert-butoxycarbonyl)amino]cyclopent-2-ene-1-carboxylic acid 
• 130931-83-8 (1S,4R)-2-azabicyclo[2,2,1]hept-5-en-3-one 
• 49805-30-3 2-azabicyclo[2.2.1.]hept-5-en-3-one 
• 134003-04-6 (1R,4S)-4-aminocyclopenten-2-ene-1-carboxylic acid 
• 426226-35-9 (+)-methyl (1R,4S)-4-aminocyclopent-2-ene-1-carboxylate hydrochloride 
• 186581-53-3 diazomethane 

Downstream Products

• 153011-43-9 (1S,cis)-tert-butyl N-[4-(hydroxymethyl)-2-cyclopenten-1-yl]carbamate 
• 102629-74-3 (-)-(4R)-4-aminocyclopentane-1-carboxylic acid 
• 321744-19-8 (1S,2S,4S)-1-(tert-butoxycarbonylamino)-2-hydroxycyclopentane-4-carboxylic acid methyl ester 
• 321744-23-4 (1R,3S,4R)-3-tert-butoxycarbonylamino-4-hydroxycyclopentanecarboxylic acid methyl ester 
• 321744-21-2 (1S,3S,4R)-3-tert-butoxycarbonylamino-4-hydroxycyclopentanecarboxylic acid methyl ester 
• 262280-14-8 (1S,2S,4R)-1-(tert-butoxycarbonylamino)-2-hydroxycyclopentane-4-carboxylic acid methyl ester 

Relevant articles and documents

CYCLOALKANE-1,3-DIAMINE DERIVATIVE

The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF

Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

Optical pure amino alcohol hydrochloride preparation method

The invention relates to a preparation method for optically pure aminoalcohol hydrochloride. The optically pure aminoalcohol hydrochloride is any one selected from optically pure aminoalcohol hydrochloride 1 and optically pure aminoalcohol hydrochloride 2 and is prepared by subjecting a compound 4 to an esterification ring-opening reaction, an amino protection reaction, an ester reduction reaction and a deprotection salt forming reaction. The optically pure aminoalcohol hydrochloride 1 or optically pure aminoalcohol hydrochloride 2 prepared in the invention can be directly used for synthesis of abacavir and carbovir. The preparation method provided by the invention has the advantages of high product optical purity, stable product quality, high product yield, a small amount of environmental pollution, low production cost, easy industrialization, etc.

OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). Formula (I) wherein: R1, R2, R3, R4, R5, Z1 and Z2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Chiral aminocyclopentene-based cycloaddition strategies to bicyclic [3.3.0] rings

Two cycloaddition methods were applied to chiral protected aminocyclopentenes 2 and 9 and provided novel bicyclic products 3 and 4 in good yields. The explanation for the observed stereochemistry was based on the sterically encumbered β-face forcing the c

FUSED CYCLOPENTYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I)

PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES

Methods of producing compositions of trans-4-amino-2-cyclopentene-1-carboxylic acid derivatives are described. Also described is an amine salt of a compound having formula A, having components present in both cis and trans structures.

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist

We report the discovery of a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist (3S,4S)-N-[(1R,3S)-3-isopropyl-3-({4-[4- (trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)cyclopentyl] -3-methoxytetrahydro-2H-pyran-4-amine (19). After evaluation in 28-day toxicology studies, compound 19 (INCB10820/PF-4178903) was selected as a clinical candidate.

Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS

Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.